Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 4
2004 2
2005 10
2006 7
2007 13
2008 22
2009 16
2010 14
2011 29
2012 28
2013 26
2014 17
2015 15
2016 11
2017 15
2018 23
2019 14
2020 18
2021 19
2022 14
2023 11
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

299 results

Results by year

Filters applied: . Clear all
Page 1
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.
Iriyama N, Iwanaga E, Kimura Y, Watanabe N, Ishikawa M, Nakayama H, Sato E, Tabayashi T, Mitsumori T, Takaku T, Nakazato T, Tokuhira M, Fujita H, Ando M, Hatta Y, Kawaguchi T. Iriyama N, et al. Among authors: fujita h. Int J Hematol. 2024 Apr 8. doi: 10.1007/s12185-024-03758-4. Online ahead of print. Int J Hematol. 2024. PMID: 38587692
Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse.
Akimoto M, Miyazaki T, Takahashi H, Saigusa Y, Takeda T, Hibino Y, Tokunaga M, Ohashi T, Matsumura A, Teshigawara H, Suzuki T, Teranaka H, Nakajima Y, Matsumoto K, Hashimoto C, Fujimaki K, Fujita H, Sakai R, Fujisawa S, Nakajima H. Akimoto M, et al. Among authors: fujita h. Int J Hematol. 2024 Feb;119(2):164-172. doi: 10.1007/s12185-023-03700-0. Epub 2024 Jan 17. Int J Hematol. 2024. PMID: 38233702
Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, Takase K, Maeda A, Sezaki N, Yokoyama H, Takada S, Hirano D, Tomikawa T, Sumi M, Yano S, Handa H, Ota S, Fujita H, Fujimaki K, Mugitani A, Kojima K, Kajiguchi T, Fujimoto K, Asou N, Usui N, Ishikawa Y, Katsumi A, Matsumura I, Miyazaki Y, Kiyoi H. Usuki K, et al. Among authors: fujita h. Int J Hematol. 2024 Feb;119(2):130-145. doi: 10.1007/s12185-023-03686-9. Epub 2023 Dec 13. Int J Hematol. 2024. PMID: 38091231
Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, Takase K, Maeda A, Sezaki N, Yokoyama H, Takada S, Hirano D, Tomikawa T, Sumi M, Yano S, Handa H, Ota S, Fujita H, Fujimaki K, Mugitani A, Kojima K, Kajiguchi T, Fujimoto K, Asou N, Usui N, Ishikawa Y, Katsumi A, Matsumura I, Kiyoi H, Miyazaki Y. Usuki K, et al. Among authors: fujita h. Int J Hematol. 2024 Jan;119(1):24-38. doi: 10.1007/s12185-023-03677-w. Epub 2023 Nov 28. Int J Hematol. 2024. PMID: 38015362
Prognostic significance of the CFA ratio for newly diagnosed acute myeloid leukemia: A multicenter retrospective study.
Sakuma T, Fujisawa S, Tanaka M, Hagihara M, Fujita H, Fujimaki K, Katsuki K, Akimoto M, Tanaka M, Matsumura A, Teshigawara H, Suzuki T, Teranaka H, Nakajima Y, Miyazaki T, Tachibana T, Matsumoto K, Sakai R, Kanamori H, Nakajima H. Sakuma T, et al. Among authors: fujita h. Hematol Oncol. 2024 Jan;42(1):e3228. doi: 10.1002/hon.3228. Epub 2023 Sep 20. Hematol Oncol. 2024. PMID: 37731313
299 results